The estimated Net Worth of Robert W Schrepfer is at least $7.98 Million dollars as of 13 May 2019. Mr. Schrepfer owns over 2,409 units of ANI Pharmaceuticals Inc stock worth over $3,037,955 and over the last 11 years he sold ANIP stock worth over $2,776,284. In addition, he makes $2,160,980 as Senior Vice President - New Business Development and Specialty Sales at ANI Pharmaceuticals Inc.
Sign up
Mr. Schrepfer ANIP stock SEC Form 4 insiders trading
Robert has made over 8 trades of the ANI Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 2,409 units of ANIP stock worth $171,352 on 13 May 2019.
The largest trade he's ever made was exercising 28,688 units of ANI Pharmaceuticals Inc stock on 11 September 2018 worth over $189,341. On average, Robert trades about 3,278 units every 47 days since 2013. As of 13 May 2019 he still owns at least 55,927 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Mr. Schrepfer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Schrepfer biography
Robert W. Schrepfer serves as Senior Vice President - New Business Development and Specialty Sales of the Company. Prior to that, Mr. Schrepfer served as the Company’s Vice President of New Business Development and Contract Manufacturing since August 2013. From 2005 to 2013, Mr. Schrepfer served as Assistant Portfolio Manager at Healthcare Value Capital, LLC, an SEC-registered healthcare investment firm. Mr. Schrepfer co-managed the firm’s private equity portfolio and oversaw investments in healthcare services, devices and specialty pharmaceuticals. Between 2003 and 2005, Mr. Schrepfer was Managing Director at Bear Stearns & Co. Inc., providing sell side research coverage of the pharmaceuticals industry. Mr. Schrepfer served as Clinical Director and Director of Outcomes and Research at the Centers for Aquatic Rehabilitation from 1997 to 2001. Mr. Schrepfer received an M.B.A. in Finance and Health Sector Management from Duke University, an M.S. in Physical Therapy from the University of Indianapolis, and a B.A. degree from the University of Kansas. He is currently a member of the Alumni Council for the Fuqua School of Business at Duke University.
What is the salary of Robert Schrepfer?
As the Senior Vice President - New Business Development and Specialty Sales of ANI Pharmaceuticals Inc, the total compensation of Robert Schrepfer at ANI Pharmaceuticals Inc is $2,160,980. There are no executives at ANI Pharmaceuticals Inc getting paid more.
How old is Robert Schrepfer?
Robert Schrepfer is 48, he's been the Senior Vice President - New Business Development and Specialty Sales of ANI Pharmaceuticals Inc since 2016. There are 12 older and 2 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.
What's Robert Schrepfer's mailing address?
Robert's mailing address filed with the SEC is C/O ANI PHARMAECUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Insiders trading at ANI Pharmaceuticals Inc
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri..., and Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
What does ANI Pharmaceuticals Inc do?
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
What does ANI Pharmaceuticals Inc's logo look like?
Complete history of Mr. Schrepfer stock trades at ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc executives and stock owners
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Robert Schrepfer,
Senior Vice President - New Business Development and Specialty Sales -
Stephen Carey,
Corporate Secretary, Vice President, Finance and Chief Financial Officer -
James Marken,
Senior Vice President - Operations and Product Development -
James G. Marken,
Sr. VP of Operations & Product Devel. -
Robert Brown,
Independent Director -
Thomas Haughey,
Independent Director -
Thomas Penn,
Independent Director -
Patrick Walsh,
Chairman of the Board -
David Nash,
Independent Director -
Jeanne Thoma,
Independent Director -
Antonio Pera,
Independent Director -
Nikhil Lalwani,
President, Chief Executive Officer, Director -
Muthasamy Shanmugam MS R.Ph.,
Head of R&D and COO of Novitium Operations -
Ori Gutwerg,
Sr. VP of Generics -
Christopher K. Mutz,
Head of Rare Diseases -
Chad Gassert,
Sr. VP of Corp. Devel. & Strategy -
Daniel Raynor,
Director -
Arthur Przybyl,
President and CEO -
Tracy Marshbanks,
Director -
Fred Holubow,
Director -
Peter A Lankau,
Director -
Charlotte C. Arnold,
Chief Financial Officer -
Renee P Tannenbaum,
Director -
Ross J Mangano,
Director -
Robert J. Jamnick,
VP, Quality & Product Develop. -
Venture Partners Ii Lp Meri...,
-
Ori Gutwerg,
SVP, GENERICS -
Christopher Mutz,
HEAD OF RARE DISEASE -
Krista Davis,
SVP, CHIEF HR OFFICER -
Chad Gassert,
SVP - CORP. DEV. & STRATEGY -
Meredith Cook,
SR. VP, GENERAL COUNSEL & SEC. -
Muthusamy Shanmugam,
HEAD OF R&D, COO-NOVITIUM OPS -
Matthew J Leonard,
Director